Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study
- PMID: 23585738
- PMCID: PMC3621740
- DOI: 10.1371/journal.pmed.1001420
Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study
Abstract
Background: Herpes zoster is common and has serious consequences, notably post-herpetic neuralgia (PHN). Vaccine efficacy against incident zoster and PHN has been demonstrated in clinical trials, but effectiveness has not been studied in unselected general populations unrestricted by region, full health insurance coverage, or immune status. Our objective was to assess zoster vaccine effectiveness (VE) against incident zoster and PHN in a general population-based setting.
Methods and findings: A cohort study of 766,330 fully eligible individuals aged ≥ 65 years was undertaken in a 5% random sample of Medicare who received and did not receive zoster vaccination between 1st January 2007 and 31st December 2009. Incidence rates and hazard ratios for zoster and PHN were determined in vaccinated and unvaccinated individuals. Analyses were adjusted for age, gender, race, low income, immunosuppression, and important comorbidities associated with zoster, and then stratified by immunosuppression status. Adjusted hazard ratios were estimated using time-updated Cox proportional hazards models. Vaccine uptake was low (3.9%) particularly among black people (0.3%) and those with evidence of low income (0.6%). 13,112 US Medicare beneficiaries developed incident zoster; the overall zoster incidence rate was 10.0 (9.8-10.2) per 1,000 person-years in the unvaccinated group and 5.4 (95% CI 4.6-6.4) per 1,000 person-years in vaccinees, giving an adjusted VE against incident zoster of 0.48 (95% CI 0.39-0.56). In immunosuppressed individuals, VE against zoster was 0.37 (95% CI 0.06-0.58). VE against PHN was 0.59 (95% CI 0.21-0.79).
Conclusions: Vaccine uptake was low with variation in specific patient groups. In a general population cohort of older individuals, zoster vaccination was associated with reduction in incident zoster, including among those with immunosuppression. Importantly, this study demonstrates that zoster vaccination is associated with a reduction in PHN. Please see later in the article for the Editors' Summary.
Conflict of interest statement
LS has undertaken consultancy for GlaxoSmithKline. DJM is on separate data safety monitoring boards for Abbott and Astellas. The authors declare no other conflicts of interest.
Figures
Similar articles
-
Effectiveness of herpes zoster vaccination in an older United Kingdom population.Vaccine. 2018 Apr 19;36(17):2371-2377. doi: 10.1016/j.vaccine.2018.02.021. Epub 2018 Mar 17. Vaccine. 2018. PMID: 29555217 Free PMC article.
-
Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.Vaccine. 2019 Aug 23;37(36):5422-5427. doi: 10.1016/j.vaccine.2019.07.004. Epub 2019 Jul 10. Vaccine. 2019. PMID: 31301920
-
Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.J Infect Dis. 2015 Oct 15;212(8):1222-31. doi: 10.1093/infdis/jiv244. Epub 2015 Jun 1. J Infect Dis. 2015. PMID: 26038400 Free PMC article.
-
Vaccination against herpes zoster in developed countries: state of the evidence.Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Epub 2013 Jan 16. Hum Vaccin Immunother. 2013. PMID: 23324598 Free PMC article. Review.
-
Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.Aging Clin Exp Res. 2009 Jun;21(3):236-43. doi: 10.1007/BF03324909. Aging Clin Exp Res. 2009. PMID: 19571648 Review.
Cited by
-
The Incidence of Herpes Zoster Complications: A Systematic Literature Review.Infect Dis Ther. 2024 Jul;13(7):1461-1486. doi: 10.1007/s40121-024-01002-4. Epub 2024 Jun 19. Infect Dis Ther. 2024. PMID: 38896390 Free PMC article. Review.
-
Based on Virtual Screening and Simulation Exploring the Mechanism of Plant-Derived Compounds with PINK1 to Postherpetic Neuralgia.Mol Neurobiol. 2024 Nov;61(11):9184-9203. doi: 10.1007/s12035-024-04098-4. Epub 2024 Apr 11. Mol Neurobiol. 2024. PMID: 38602654
-
Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.Hum Vaccin Immunother. 2024 Dec 31;20(1):2327145. doi: 10.1080/21645515.2024.2327145. Epub 2024 Mar 15. Hum Vaccin Immunother. 2024. PMID: 38488143 Free PMC article.
-
Willingness to vaccinate against herpes zoster in Chinese urban population: a mixed-methods study.BMJ Open. 2023 Dec 7;13(12):e079115. doi: 10.1136/bmjopen-2023-079115. BMJ Open. 2023. PMID: 38149414 Free PMC article.
-
Shingles Vaccine Uptake Among Older Adults: Identifying Early, Later, and Nonadopters.AJPM Focus. 2023 Sep 21;2(4):100143. doi: 10.1016/j.focus.2023.100143. eCollection 2023 Dec. AJPM Focus. 2023. PMID: 37920403 Free PMC article.
References
-
- Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, et al. (2007) A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82: 1341–1349. - PubMed
-
- Oxman M, Levin M, Johnson G, Schmader K, Straus S, et al. (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352: 2271–2284. - PubMed
-
- Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, et al. (2011) Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305: 160–166. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
